Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 20/20 | 0.55 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.55 |
| ▸ | OXTR | P30559 | 6/20 | 0.55 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.54 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786304 | 0.90 | AVPR1B (0.63) | AVPR1BAVPR1AOXTRAVPR2 | |
| SCHEMBL1589023 | 0.90 | AVPR1B (0.46) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL16178114 | 0.90 | AVPR1B (0.63) | AVPR1BAVPR1AOXTRAVPR2 | |
| SCHEMBL1588385 | 0.85 | AVPR1B (0.50) | AVPR1BAVPR1AOXTRAVPR2 | |
| SCHEMBL16672308 | 0.83 | AVPR1B (0.57) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL1590457 | 0.82 | AVPR1B (0.61) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL1465192 | 0.82 | AVPR1B (0.64) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL14562638 | 0.80 | AVPR1B (0.64) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL2075631 | 0.80 | AVPR1B (0.64) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL14562640 | 0.80 | AVPR1B (0.64) | AVPR1BAVPR1AOXTRAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20110092516-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092516-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885AVPR1A 3/4885OXTR 4/4885 |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885AVPR1A 3/4885OXTR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.